Monoamine metabolites level in CSF is related to the 5-HTT gene polymorphism in treatment-resistant depression

Neuropsychopharmacology

Volumn 32, Issue 10, 2007, Pages 2143-2151

  Kishida, Ikuko ^a,b   Aklillu, Eleni ^a   Kawanishi, Chiaki ^b   Bertilsson, Leif ^a   Ågren, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

5 HIAA; 5 HTTLPR; Cerebrospinal fluid; Depression; HVA; Serotonin transporter

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; HOMOVANILLIC ACID; MONOAMINE; MOOD STABILIZER; SEROTONIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; DEPRESSION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MOOD DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TANDEM REPEAT;

ADULT; AGED; BIOGENIC MONOAMINES; BRAIN CHEMISTRY; DEPRESSIVE DISORDER; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GENOTYPE; HOMOVANILLIC ACID; HUMANS; HYDROXYINDOLEACETIC ACID; MALE; METHOXYHYDROXYPHENYLGLYCOL; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; TANDEM REPEAT SEQUENCES; UP-REGULATION;

EID: 34548687990     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301336     Document Type: Article

References (44)

1. Asberg M (1997). Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 836: 158-181.
2. Asberg M, Bertilsson L, Martensson B, Scalia-Tomba GP, Thoren P, Traskman-Bendz L (1984). CSF monoamine metabolites in melancholia. Acta Psychiatr Scand 69: 201-219.
3. Ågren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ (1986). Interacting neurotransmitter systems. A non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 20: 175-193.
4. Blennow K, Wallin A, Gottfries CG, Karlsson I, Mansson JE, Skoog I et al (1993). Cerebrospinal fluid monoamine metabolites in 114 healthy individuals 18-88 years of age. Eur Neuropsychopharmacol 3: 55-61.
5. Clarke AS, Hedeker DR, Ebert MH, Schmidt DE, McKinney WT, Kraemer GW (1996). Rearing experience and biogenic amine activity in infant rhesus monkeys. Biol Psychiatry 40: 338-352.
6. Collier DA, Stober G, Li T, Heils A, Catalano M, Di Bella D et al (1996). A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders. Mol Psychiatry 1: 453-460.
7. Crown WH, Finkelstein S, Berndt ER, Ling D, Poret AW, Rush AJ et al (2002). The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 63: 963-971.
8. Endicott J, Cohen J, Nee J, Fleiss J, Sarantakos S (1981). Hamilton depression rating scale. Extracted from regular and change versions of the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 38: 98-103.
9. Endicott J, Spitzer RL (1978). A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 35: 837-844.
10. Fiskerstrand CE, Lovejoy EA, Quinn JP (1999). An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458: 171-174.
11. Furlong RA, Ho L, Walsh C, Rubinsztein JS, Jain S, Paykel ES et al (1998). Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders. Am J Med Genet 81: 58-63.
12. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612.
13. Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A (2004). Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 22: 363-373.
14. Hamilton M (1967). Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278-296.
15. Hanna GL, Himle JA, Curtis GC, Koram DQ, Veenstra-Vander-Weele J, Leventhal BL et al (1998). Serotonin transporter and seasonal variation in blood serotonin in families with obsessive-compulsive disorder. Neuropsychopharmacology 18: 102-111.
16. Heilig M, Zachrisson O, Thorsell A, Ehnvall A, Mottagui-Tabar S, Sjogren M et al (2004). Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J Psychiatr Res 38: 113-121.
17. Heinz A, Higley JD, Gorey JG, Saunders RC, Jones DW, Hommer D et al (1998). In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. Am J Psychiatry 155: 1023-1028.
18. Heinz A, Jones DW, Bissette G, Hommer D, Ragan P, Knable M et al (2002). Relationship between cortisol and serotonin metabolites and transporters in alcoholism (correction of alcolholism). Pharmacopsychiatry 35: 127-134.
19. Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D et al (2000). A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 47: 643-649.
20. Higley JD, Thompson WW, Champoux M, Goldman D, Hasert MF, Kraemer GW et al (1993). Paternal and maternal genetic and environmental contributions to cerebrospinal fluid monoamine metabolites in rhesus monkeys (Macaca mulatta). Arch Gen Psychiatry 50: 615-623.
21. Jonsson E, Sedvall G, Brene S, Gustavsson JP, Geijer T, Terenius L et al (1996). Dopamine-related genes and their relationships to monoamine metabolites in CSF. Biol Psychiatry 40: 1032-1043.
22. Jonsson EG, Nothen MM, Gustavsson JP, Neidt H, Bunzel R, Propping P et al (1998). Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res 79: 1-9.
23. Kawanishi C, Lundgren S, Agren H, Bertilsson L (2004). Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59: 803-807.
24. Kim DK, Tolliver TJ, Huang SJ, Martin BJ, Andrews AM, Wichems C et al (2005). Altered serotonin synthesis, turnover and dynamic regulation in multiple brain regions of mice lacking the serotonin transporter. Neuropharmacology 49: 798-810.
25. Kreiss DS, Lucki I (1995). Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. J Pharmacol Exp Ther 274: 866-876.
26. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S et al (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531.
27. Lin PY, Tsai G (2004). Association between serotonin transporter gene promoter polymorphism and suicide: results of a metaanalysis. Biol Psychiatry 55: 1023-1030.
28. Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, McFinton PR et al (1998). Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry 155: 207-213.
29. MacKenzie A, Quinn J (1999). A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci USA 96: 15251-15255.
30. Malison RT, Price LH, Berman R, van Dyck CH, Pelton GH, Carpenter L et al (1998). Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl) tropane and single photon emission computed tomography. Biol Psychiatry 44: 1090-1098.
31. Mann JJ (1998). The neurobiology of suicide. Nat Med 4: 25-30.
32. Meltzer HY, Lowy MT (1987). The serotonin hypothesis of depression. In: Meltzer HY (ed). Psychopharmacology: Third Generation of Progress. Raven Press: New York. pp 513-526.
33. Nakamura M, Ueno S, Sano A, Tanabe H (2000). The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 5: 32-38.
34. Nemeroff CB, Knight DL, Franks J, Craighead WE, Krishnan KR (1994). Further studies on platelet serotonin transporter binding in depression. Am J Psychiatry 151: 1623-1625.
35. Ogilvie AD, Battersby S, Bubb VJ, Fink G, Harmar AJ, Goodwim GM et al (1996). Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347: 731-733.
36. Owens MJ, Nemeroff CB (1994). Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40: 288-295.
37. Parsey RV, Hastings RS, Oquendo MA, Hu X, Goldman D, Huang YY et al (2006). Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 163: 48-51.
38. Rudnick G, Clark J (1993). From synapse to vesicle: the reuptake and storage of biogenic amine neurotransmitters. Biochim Biophys Acta 1144: 249-263.
39. Schneider SRD, Excoffier L (2000). Arlequin: A Software for Population Genetics Data Analysis. Ver 2.000. Genetics and Biometry Lab, Department of Anthropology, University of Geneva, Geneva.
40. Serretti A, Lattuada E, Catalano M, Smeraldi E (1999). Serotonin transporter gene not associated with psychotic symptomatology of mood disorders. Psychiatry Res 86: 59-65.
41. Serretti A, Lilli R, Lorenzi C, Lattuada E, Cusin C, Smeraldi E (2002). Serotonin transporter gene (5-HTTLPR) and major psychoses. Mol Psychiatry 7: 95-99.
42. Smits KM, Smits LJ, Schouten JS, Stelma FF, Nelemans P, Prins MH (2004). Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 9: 433-441.
43. Stanley M, Traskman-Bendz L, Dorovini-Zis K (1985). Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 37: 1279-1286.
44. Williams RB, Marchuk DA, Gadde KM, Barefoot JC, Grichnik K, Helms MJ et al (2003). Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 28: 533-541.